Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma × vistusertib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Solid Tumor 2 Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Recurrence 1 Non-small Cell Lung Cancer Metastatic 1 Meningioma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Cyclophosphamide 214 Rituximab 198 Etoposide 124 Filgrastim 101 Vincristine 98 Doxorubicin 91 Cytarabine 82 Prednisone 77 Radiotherapy 73 Methotrexate 70 Melphalan 65 fludarabine phosphate 64 Peripheral Blood Stem Cell Transplantation 64 Busulfan 52 Dexamethasone 45 Carmustine 42 Tacrolimus 39 Mycophenolic Acid 38 fludarabine 37 Granulocyte Colony-Stimulating Factor 37 Ifosfamide 35 Antilymphocyte Serum 35 Whole-Body Irradiation 31 sargramostim 29 Gemcitabine 28 Bortezomib 28 Cyclosporine 27 Methylprednisolone 25 Bendamustine Hydrochloride 25 Cisplatin 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02752204 2020-11-05

TORCH

University of Birmingham

Phase 2 Completed

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡